交叉训练数字疗法治疗儿童ADHD:随机对照试验方案
本研究为多中心、开放标签、随机对照试验,拟纳入210名6-12岁ADHD患儿,随机分为药物组、数字疗法组和联合组,评估整合神经反馈与执行功能训练的交叉训练数字疗法的疗效与可接受性。主要结局为8周时SNAP-IV总分变化,数字疗法组与药物组进行非劣效检验(界值Δ=4分),联合组与药物组进行优效检验。
要点
- 交叉训练数字疗法整合神经反馈与执行功能训练,针对ADHD认知与行为机制。
- 主要结局为8周SNAP-IV总分变化,非劣效界值Δ=4分。
- 联合组与药物组优效定义为差值双侧95%CI下限大于0。
核心结论
- 该试验旨在评估交叉训练数字疗法对6-12岁ADHD患儿的疗效与可接受性。
- 结果可能为ADHD患儿提供非药物干预或补充治疗选择。
研究设计与样本
- 多中心、开放标签、随机对照试验。
- 计划纳入210名6-12岁ADHD患儿,随机分为药物组、数字疗法组和联合组。
- 数字疗法组接受家庭数字训练,药物组接受哌甲酯,联合组接受两者。
主要发现
- 主要结局为随机化后8周SNAP-IV总分较基线的变化。
- 数字疗法组与药物组进行非劣效检验,界值Δ=4分。
- 联合组与药物组优效定义为差值双侧95%CI下限大于0。
- 将评估数字疗法的依从性和潜在副作用。
关键数值与推荐
- 非劣效界值Δ=4分(SNAP-IV总分变化,数字疗法组对比药物组)。
- 优效标准为联合组与药物组差值双侧95%CI下限大于0。
临床怎么用
- 若达到非劣效,数字疗法可作为ADHD的非药物干预选择。
- 联合治疗可能作为补充治疗选项,需结合依从性与副作用评估。
局限性
- 开放标签设计可能引入偏倚。
- 原文未报告样本量计算依据及盲法实施细节。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Attention-deficit/hyperactivity disorder (ADHD) in children can result in academic and occupational failure, poor socialization, and an increased risk of accidental injuries. Digital therapeutics (DTx) leverage computers and smartphones to provide game-based treatments targeting ADHD's cognitive and behavioral aspects. Although the evidence base for DTx in ADHD is expanding, most DTx focus on a single mechanism without leveraging potential synergies between them. This study aims to evaluate the effectiveness of a cross-training DTx for children aged 6-12 with ADHD. METHODS: The DTx study is a multicenter, open-label, randomized controlled trial that employs a cross-training approach integrating neurofeedback and executive function training. A total of 210 participants will be randomly assigned to one of three groups: the medication group (MED), the DTx group (DTX), or the combination group (COM). DTX will receive home‑based digital training, MED will receive methylphenidate, and COM will receive both. The primary outcome is change in Swanson, Nolan, and Pelham Rating Scale (SNAP‑IV) total score from baseline to 8 weeks post-randomization. Non‑inferiority will be tested between DTX and MED with a non-inferiority margin of Δ = 4 points; superiority between COM and MED will be defined as the lower bound of the two‑sided 95% confidence interval for the difference being greater than 0. DISCUSSION: The clinical trial protocol presented here outlines a randomized controlled trial that evaluates DTx utilizing cross-training approach. The aim of this trial is to assess the efficacy and acceptability of the cross-training DTx for children aged 6 to 12 years with ADHD. The primary outcome is the degree of improvement in the core symptoms of ADHD (measured by SNAP‑IV). Additionally, we will evaluate compliance and potential side effects associated with the DTx. The results of this study may provide an optional non-pharmacological intervention/supplementary treatment option for children with ADHD. TRIAL REGISTRATION: NCT06369714. Registered on 17 April 2024. https://clinicaltrials.gov/study/NCT06369714 .
引用
- Zhao X, Cai Y, Zhang X, et al. Cross-training digital therapeutics for pediatric ADHD: study protocol for a randomized controlled trial. Trials. 2026. PMID: 42152117. doi:10.1186/s13063-026-09775-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。